forigerimod

Forigerimod is a synthetic 21-amino acid phosphopeptide derived from the U1 small nuclear ribonucleoprotein (snRNP) 70K protein, phosphorylated at serine position 140. It is being developed primarily for the treatment of systemic lupus erythematosus (SLE). Forigerimod acts as an immunomodulator by specifically modulating the activation of auto-reactive CD4+ T-cells, targeting upstream T-cell activation to suppress deleterious immune responses while preserving normal immune function. This mechanism distinguishes it from other SLE therapies that act further downstream in the immune cascade. The drug is administered subcutaneously and has also been investigated in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), with preclinical studies in asthma, gout, and periodontitis[2][5][6][8].

Brand names

Lupuzor

Other names

peptide P140forigerimod acetate